Ionis Pharmaceuticals IONS Ionis Operations — Drug Discovery Expenses

Similar metrics at other companies

VRTXPharmaceuticals — Research expenses

$205M-0.5%

ARWROperating Segment — Discovery costs

$18.5M+24.9%

ROIVOther development and discovery programs — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)

$13.43M-3.9%

BIIBBIIB080 — Research and development expense

$2.5M—

EXELReportable Segment — Drug discovery

$19.48M+6.7%

LLYEarly-stage — R&D

$1.27B+27.9%

Questions, answered.

What is Ionis Pharmaceuticals's ionis operations — drug discovery expenses?

Ionis Pharmaceuticals (IONS) reported ionis operations — drug discovery expenses of $28.56M in Q1 2026.

How has Ionis Pharmaceuticals's ionis operations — drug discovery expenses changed year-over-year?

Ionis Pharmaceuticals's ionis operations — drug discovery expenses increased by 5.8% year-over-year, from $26.99M to $28.56M.

What is the long-term trend for Ionis Pharmaceuticals's ionis operations — drug discovery expenses?

Over 3 years (2022 to 2025), Ionis Pharmaceuticals's ionis operations — drug discovery expenses has grown at a -11.6% compound annual growth rate (CAGR), from $181.3M to $125.16M.

What does ionis operations — drug discovery expenses mean?

Costs related to the early-stage research and identification of new drug candidates.

How do you interpret ionis operations — drug discovery expenses?

An increase reflects higher investment in future pipeline growth, while a decrease may signal a shift toward later-stage development.

How does ionis operations — drug discovery expenses compare across companies?

Comparable to early-stage R&D or discovery-phase research expenses at peer biotech firms.